Evolocumab: No hint of added benefit

December 22, 2015

Evolocumab (trade name: Repatha) has been approved since July 2015 for two therapeutic indications: on the one hand, for hypercholesterolaemia or mixed dyslipidaemia, and on the other, for homozygous familial hypercholesterolaemia. The drug is an option for patients whose cholesterol levels are not adequately lowered by diet and other drugs. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether evolocumab offers an added benefit over the appropriate comparator therapy. Due to a lack of suitable data, no such added benefit can be derived from the dossier for any of the two therapeutic indications.

The G-BA distinguished between a total of six treatment situations

Hypercholesterolaemia is diagnosed when the LDL cholesterol levels in the blood are too high. In mixed dyslipidaemia, triglyceride levels may also be elevated. Homozygous familial hypercholesterolaemia is a very rare hereditary form. If left untreated, all of these conditions can lead to cardiovascular diseases (coronary heart disease, arteriosclerosis); in hereditary homozygous hypercholesterolaemia, cardiovascular disease may already occur in childhood.

Standard treatment options include diet together with other lipid-lowering drugs or, if this is no longer effective, LDL apheresis, a procedure similar to dialysis. The Federal Joint Committee (G-BA) differentiated between a total of six treatment situations and research questions for the assessment, and specified an appropriate comparator therapy for each of them.

Twelve-week studies are far too short to investigate long-term treatment

The manufacturer presented no studies in its dossier for one treatment situation in one of the two therapeutic indications and for two treatment situations in the other therapeutic indication. The dossier contained data from randomized controlled trials for the remaining three treatment situations. In these studies however, the patients were treated and observed for only twelve weeks.

Since these are chronic diseases and evolocumab is used in long-term treatment, however, studies with a minimum duration of one year are required to assess benefit and harm. Hence there is no hint of an added benefit in comparison with the appropriate comparator therapy for any of the therapeutic indications and for any of the treatment situations.
-end-
G-BA decides on the extent of added benefit

This dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the Website gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language Information.

More English-language information will be available soon (Sections I 2.1 to I 2.6 and II 2.1 to II 2.5 of the dossier assessment as well as subsequently published health information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.

Institute for Quality and Efficiency in Health Care

Related Cholesterol Levels Articles from Brightsurf:

Low 'good' cholesterol levels found in Latin America and the Caribbean
Low levels of HDL cholesterol, the so-called 'good' cholesterol, are the most common lipid disorder in countries in Latin America and the Caribbean, a new meta-analysis published in eLife shows.

Cholesterol levels dropping in Western nations but rising in Asia
Cholesterol levels are declining sharply in western nations, but rising in low- and middle-income nations - particularly in Asia, according to a study of global cholesterol levels, which involve researchers at the University of Gothenburg.

Cholesterol levels dropping in Western nations -- but rising in Asia
Cholesterol levels are declining sharply in Western nations, but rising in low- and middle-income nations - particularly in Asia, suggests the largest ever study of global cholesterol levels.

Sharp drop in Australia's bad cholesterol levels -- but rising in Asia and Pacific
The proportion of Australians with bad cholesterol levels has dropped significantly, while Asian and Pacific countries recorded a sharp rise, according to the world's largest study on the condition.

Evinacumab cuts cholesterol levels by half in patients with HoFH
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol to near-normal levels among patients with a rare cholesterol disorder, meeting the primary endpoint in the first randomized placebo-controlled trial of the drug, which is being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Cholesterol levels in American adults declining since 2013 guideline release
The implementation of the 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol has led to improved overall cholesterol levels for American adults, especially those on cholesterol lowering medications, according to a study published today in the Journal of the American College of Cardiology that examined the impact of the highly anticipated guideline several years after release.

European guidelines on lipid control advocate 'lower is better' for cholesterol levels
Low-density lipoprotein (LDL) cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.

Levels of 'ugly cholesterol' in the blood are much higher than previously imagined
The amount of remnant particle cholesterol in the blood, the so-called ugly cholesterol, is much higher than previously believed.

Did cholesterol levels improve among us kids, adolescents?
This study examined cholesterol levels in children and adolescents in the US from 1999 to 2016.

Only half of US kids and teens have ideal cholesterol levels
Cholesterol levels in US youth have improved from 1999 to 2016, but only half of children and adolescents are in the ideal range and 25% are in the clinically high range, according to a study published in JAMA, led by Amanda Marma Perak, M.D.

Read More: Cholesterol Levels News and Cholesterol Levels Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.